PROCEPT BioRobotics

PROCEPT BioRobotics is a commercial-stage medical device company founded in 2009, specializing in surgical robotics for urology. The firm designs and manufactures image-guided robotic systems that utilize heat-free waterjet ablation to treat benign prostatic hyperplasia (BPH). By integrating real-time multidimensional imaging with automated robotics, the company provides a proprietary platform that ensures consistent, durable outcomes for patients regardless of prostate size or surgeon experience.

Operating with 500-1,000 employees, the organization maintains a robust operational footprint focused on advancing minimally invasive urologic surgery. Meet PROCEPT BioRobotics's team to learn about their leadership and the technical expertise driving their innovation in the medtech sector. The company’s commitment to clinical-stage development and patient care remains central to its growth strategy within the competitive medical device landscape.

PROCEPT BioRobotics trades on the NASDAQ under the ticker symbol PRCT. With annual revenue reaching $322.0M, the company demonstrates significant market traction in the manufacturing of specialized surgical robots. Explore financial highlights to review detailed metrics and funding history. The firm continues to compete with major industry players like Accuray and UroLift, leveraging its unique waterjet technology to maintain a strong market position in North America and beyond.